<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492998</url>
  </required_header>
  <id_info>
    <org_study_id>2008.501-02</org_study_id>
    <nct_id>NCT01492998</nct_id>
  </id_info>
  <brief_title>Role of FXR in Hepatitis C Virus Replication</brief_title>
  <acronym>GGST</acronym>
  <official_title>Study of the Role of the Biliary Salts Nuclear Receptor FXR in Hepatitis C Virus Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vitro in the hepatitis C virus (HCV) replicon system, modulation of the biliary salts
      nuclear receptor FXR by either agonists or antagonists respectively increases or decreases
      the replication of HCV (J Hepatol, 2008, 48: 192-9). One antagonist of FXR is a vegetal
      sterol, guggulsterone, that is extracted from the Commiphora mukul tree and that has already
      been given safely to hyper cholesterolemic patients in a clinical trial (JAMA 2003, 290:
      765-72). The aim of this trial is to test the effect of the FXR antagonist guggulsterone
      given orally, three times a day, on the viral load in 15 HCV genotype 1 chronically infected
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the HCV plasmatic viral load while taking the FXR inhibitor guggulsterone.</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification of the fraction of the circulating viral forms associated with apolipoprotein B</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Guggulsterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm of 15 chronically HCV genotype one infected patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>guggulsterone, a natural FXR antagonist.</intervention_name>
    <description>Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone</description>
    <arm_group_label>Guggulsterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients infected by HCV genotype 1, with anti-HCV antibodies, non responders to
             at least one first line of therapy

          -  Viral load &gt; 1 x 105 UI/mL for more than 6 months and not treated for at least the
             last two months.

          -  METAVIR score &lt; F4

        Exclusion Criteria:

          -  Alcohol intake &gt; 20 g/day

          -  Immuno - suppressive therapy

          -  Obesity BMI &gt; 30, diabetes

          -  Dyslipidemia requiring specific therapy

          -  Liver cirrhosis or carcinoma

          -  HIV or HBV co-infections

          -  Other liver diseases

          -  Major organ failures

          -  Therapy with cytochrome P450 metabolized drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Trépo, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Maynard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of hepatology, Hospices Civils de Lyon, Hôtel Dieu</name>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Biliary salts</keyword>
  <keyword>Farnesoid X receptor</keyword>
  <keyword>Guggulsterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

